Since low dose IL-2 (ld-IL-2) administration selectively expands Treg cells in both mice and humans [172,173], the effects of ld-IL-2 in ALS was evaluated through a phase-2a, randomized, double-blind, placebo-controlled trial. This evidence concerns the gene IL2 and amyotrophic lateral sclerosis.